Business Description
SinoMab BioScience Ltd
ISIN : HK0000544194
Total Employee Number:
95Compare
Compare
Traded in other countries / regions
03681.Hong Kong4VF.Germany IPO Date
2026-02-18Description
SinoMab BioScience Ltd is a biopharmaceutical company focused on the research, development, manufacturing, and commercialisation of therapeutics for the treatment of immunological diseases, mainly monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential first-in-class mAb against CD22 for the treatment of rheumatoid arthritis (RA) and other immunological diseases. In addition, the company possesses other potential first-in-class drug candidates (like SM17, SN1011, SM06, SM09, etc.) some of which are already in the clinical stage, with their indications covering rheumatoid arthritis (RA), Sjogren's syndrome (SS), systemic lupus erythematosus (SLE), atopic dermatitis (AD), idiopathic pulmonary fibrosis (IPF), asthma, and other diseases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.77 | |||||
Equity-to-Asset | 0.53 | |||||
Debt-to-Equity | 0.74 | |||||
Debt-to-EBITDA | -1.53 | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 38.8 | |||||
3-Year EPS without NRI Growth Rate | 32.2 | |||||
3-Year FCF Growth Rate | 43.1 | |||||
3-Year Book Growth Rate | -9.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 46.96 | |||||
9-Day RSI | 44.52 | |||||
14-Day RSI | 44.32 | |||||
3-1 Month Momentum % | 27.27 | |||||
6-1 Month Momentum % | -30 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.35 | |||||
Quick Ratio | 1.35 | |||||
Cash Ratio | 1.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -10.2 | |||||
Shareholder Yield % | -23.05 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -50.18 | |||||
ROA % | -24.18 | |||||
ROIC % | -25.02 | |||||
3-Year ROIIC % | 297.28 | |||||
ROC (Joel Greenblatt) % | -36.71 | |||||
ROCE % | -31.01 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 3.72 | |||||
Price-to-Tangible-Book | 3.9 | |||||
EV-to-EBIT | -8.07 | |||||
EV-to-EBITDA | -8.07 | |||||
EV-to-FCF | -17.32 | |||||
Earnings Yield (Greenblatt) % | -12.4 | |||||
FCF Yield % | -6.2 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
SinoMab BioScience Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.017 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 44.32 | ||
| 14-Day ATR (€) | 0.006337 | ||
| 20-Day SMA (€) | 0.11945 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 0.102 - 0.22 | ||
| Shares Outstanding (Mil) | 1,386.64 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
SinoMab BioScience Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
SinoMab BioScience Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
SinoMab BioScience Ltd Frequently Asked Questions
What is SinoMab BioScience Ltd(FRA:4VF)'s stock price today?
The current price of FRA:4VF is €0.12. The 52 week high of FRA:4VF is €0.22 and 52 week low is €0.10.
When is next earnings date of SinoMab BioScience Ltd(FRA:4VF)?
The next earnings date of SinoMab BioScience Ltd(FRA:4VF) is .
Does SinoMab BioScience Ltd(FRA:4VF) pay dividends? If so, how much?
SinoMab BioScience Ltd(FRA:4VF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers